Anne-Christine Bay-Jensen

The disease modifying osteoarthritis drug (DMOAD): Is it in the horizon?

Biochemical markers of joint tissue turnover.

Which elements are involved in reversible and irreversible cartilage degradation in osteoarthritis?

Suppression of MMP activity in bovine cartilage explants cultures has little if any effect on the release of aggrecanase-derived aggrecan fragments.

Aggrecanase- and matrix metalloproteinase-mediated aggrecan degradation is associated with different molecular characteristics of aggrecan and separated in time ex vivo.

Application of biochemical markers in development of drugs for treatment of osteoarthritis.

Serum markers of liver fibrosis: combining the BIPED classification and the neo-epitope approach in the development of new biomarkers.

Procollagen type I N-terminal propeptide (PINP) is a marker for fibrogenesis in bile duct ligation-induced fibrosis in rats.

Investigation of the direct effects of salmon calcitonin on human osteoarthritic chondrocytes.

Novel combinations of Post-Translational Modification (PTM) neo-epitopes provide tissue-specific biochemical markers--are they the cause or the consequence of the disease?

Oral salmon calcitonin--pharmacology in osteoporosis.

Enzyme-linked immunosorbent assay (ELISAs) for metalloproteinase derived type II collagen neoepitope, CIIM--increased serum CIIM in subjects with severe radiographic osteoarthritis.

Measurement of matrix metalloproteinase 9-mediated collagen type III degradation fragment as a marker of skin fibrosis.

Biochemical markers of ongoing joint damage in rheumatoid arthritis--current and future applications, limitations and opportunities.

Glucocorticoids exert context-dependent effects on cells of the joint in vitro.

Molecular serum and urine marker repertoire supporting clinical research on joint diseases.

Investigation of chondrocyte hypertrophy and cartilage calcification in a full-depth articular cartilage explants model.

The inhibitory effect of salmon calcitonin on tri-iodothyronine induction of early hypertrophy in articular cartilage.

Extracellular matrix remodeling: the common denominator in connective tissue diseases. Possibilities for evaluation and current understanding of the matrix as more than a passive architecture, but a key player in tissue failure.

Future detection and monitoring of diabetes may entail analysis of both β-cell function and volume: how markers of β-cell loss may assist.

Quantification of "end products" of tissue destruction in inflammation may reflect convergence of cytokine and signaling pathways -- implications for modern clinical chemistry.

Extracellular matrix specific protein fingerprints measured in serum can separate pancreatic cancer patients from healthy controls.

Rheumatoid arthritis: a case for personalized health care?

The active form of MMP-3 is a marker of synovial inflammation and cartilage turnover in inflammatory joint diseases.

Serum biomarkers reflecting specific tumor tissue remodeling processes are valuable diagnostic tools for lung cancer.

Cartilage turnover reflected by metabolic processing of type II collagen: a novel marker of anabolic function in chondrocytes.

Novel insights into the function and dynamics of extracellular matrix in liver fibrosis.

Clinical Drug Development Using Dynamic Biomarkers to Enable Personalized Health Care in COPD.

Diagnosis of Osteoarthritis by Cartilage Surface Smoothness Quantified Automatically from Knee MRI.

Characterization of an Ex vivo Femoral Head Model Assessed by Markers of Bone and Cartilage Turnover.

Fragments of Citrullinated and MMP-degraded Vimentin and MMP-degraded Type III Collagen Are Novel Serological Biomarkers to Differentiate Crohn's Disease from Ulcerative Colitis.

Serum cartilage oligomeric matrix protein and development of radiographic and painful knee osteoarthritis. A community-based cohort of middle-aged women.

Synovitis biomarkers: ex vivo characterization of three biomarkers for identification of inflammatory osteoarthritis.

Neo-Epitopes--Fragments of Cartilage and Connective Tissue Degradation in Early Rheumatoid Arthritis and Unclassified Arthritis.

Intercritical circulating levels of neo-epitopes reflecting matrixmetalloprotease-driven degradation as markers of gout and frequent gout attacks.

Chondrocyte activity is increased in psoriatic arthritis and axial spondyloarthritis.

Remodeling of the Tumor Microenvironment Predicts Increased Risk of Cancer in Postmenopausal Women: The Prospective Epidemiologic Risk Factor (PERF I) Study.

Type I and III collagen turnover is increased in axial spondyloarthritis and psoriatic arthritis. Associations with disease activity and diagnostic capacity.

Nidogen-1 Degraded by Cathepsin S can be Quantified in Serum and is Associated with Non-Small Cell Lung Cancer.

Biomarker of extracellular matrix remodelling C1M and proinflammatory cytokine interleukin 6 are related to synovitis and pain in end-stage knee osteoarthritis patients.

Unique insight into microenvironmental changes in colorectal cancer: assessment of matrix metalloprotease-mediated molecular changes in human colorectal tumor tissue and corresponding non-neoplastic adjacent tissue.

Suppression of active, but not total MMP-3, is associated with treatment response in a phase III clinical study of rheumatoid arthritis.

Changes of patient-reported outcomes and protein fingerprint biomarkers after exercise therapy for axial spondyloarthritis.

Excessive matrix metalloprotease-mediated degradation of interstitial tissue (type I collagen) independently predicts short-term survival in an observational study of postmenopausal women diagnosed with cancer.

Ulcerative colitis, Crohn's disease, and irritable bowel syndrome have different profiles of extracellular matrix turnover, which also reflects disease activity in Crohn's disease.

Biochemical marker discovery, testing and evaluation for facilitating OA drug discovery and development.

Blockade of GM-CSF pathway induced sustained suppression of myeloid and T cell activities in rheumatoid arthritis.

Sprifermin (rhFGF18) modulates extracellular matrix turnover in cartilage explants ex vivo.

Identification of pain categories associated with change in pain in patients receiving placebo: data from two phase 3 randomized clinical trials in symptomatic knee osteoarthritis.

IL-6 receptor inhibition modulates type III collagen and C-reactive protein degradation in rheumatoid arthritis patients with an inadequate response to anti-tumour necrosis factor therapy: analysis of connective tissue turnover in the tocilizumab RADIATE study.

Increased remodelling of interstitial collagens and basement membrane is suppressed by treatment in patients with rheumatoid arthritis: serological evaluation of a one-year prospective study of 149 Japanese patients.

Aggrecanase degradation of type III collagen is associated with clinical knee pain.

Protein biomarkers associated with pain mechanisms in osteoarthritis.

Type IV collagen metabolism is associated with disease activity, radiographic progression and response to tocilizumab in rheumatoid arthritis.

Bone and Soft Tissue Turnover in Relation to All-cause Mortality in Postmenopausal Women.

Tofacitinib and TPCA-1 exert chondroprotective effects on extracellular matrix turnover in bovine articular cartilage ex vivo.

A Novel High Sensitivity Type II Collagen Blood-Based Biomarker, PRO-C2, for Assessment of Cartilage Formation.

The VICM biomarker is released from activated macrophages and inhibited by anti-GM-CSFRα-mAb treatment in rheumatoid arthritis patients.

Molecular taxonomy of osteoarthritis for patient stratification, disease management and drug development: biochemical markers associated with emerging clinical phenotypes and molecular endotypes.

Serum biomarkers of collagen turnover as potential diagnostic tools in diffuse systemic sclerosis: A cross-sectional study.

Soluble biochemical markers of osteoarthritis: Are we close to using them in clinical practice?

Osteoarthritis year in review 2018: biomarkers (biochemical markers).

Serological biomarker profiles of rapidly progressive osteoarthritis in tanezumab-treated patients.

Metabolites of C-reactive protein and vimentin are associated with disease activity of axial spondyloarthritis.

GPDPLQ-A Type II Collagen Neo-Epitope Biomarker of Osteoclast- and Inflammation-Derived Cartilage Degradation in vitro.

Association of metabolites reflecting type III and VI collagen formation with modified Rodnan skin score in systemic sclerosis - a cross-sectional study.

Osteoarthritis phenotypes and novel therapeutic targets.

Serological Assessment of the Quality of Wound Healing Processes in Crohn's Disease.

Associations between biomarkers of bone and cartilage turnover, gender, pain categories and radiographic severity in knee osteoarthritis.

Biochemical markers in osteoarthritis with lessons learned from osteoporosis.